SUPN
Supernus Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
41.84
close · 2026-10-29
value
49
cheaper than peers49
quality
75
stronger fundamentals75
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 9.78× | 64 |
| price to book | 2.36× | 61 |
| price to sales | 2.93× | 45 |
| EV to EBITDA | 18.62× | 35 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 3.9% | 93 |
| revenue growth | 32.4% | 85 |
| return on equity | -10.5% | 40 |
| operating margin | -2.5% | 36 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | $84.6M |
| employees | 778 |
| first trade | 2012-05-01 |
| next earnings | 2026-10-29 |
| fundamentals updated | 2026-10-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.68 | 1.32 | 0.02 | 1.04 |
| free cash flow | $46.0M | $171.2M | $110.5M | $116.4M |
| net income | -$38.5M | $73.9M | $1.3M | $60.7M |
| revenue | $719.0M | $661.8M | $607.5M | $667.2M |
| unusual items | -$25.4M | $6.1M | -$18.7M | $510,000 |